These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32470203)

  • 1. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation.
    Stader F; Courlet P; Kinvig H; Battegay M; Decosterd LA; Penny MA; Siccardi M; Marzolini C
    Br J Clin Pharmacol; 2021 Feb; 87(2):458-470. PubMed ID: 32470203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
    Stader F; Courlet P; Decosterd LA; Battegay M; Marzolini C
    Clin Pharmacol Ther; 2021 Apr; 109(4):1025-1029. PubMed ID: 33521960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly.
    Stader F; Courlet P; Kinvig H; Penny MA; Decosterd LA; Battegay M; Siccardi M; Marzolini C
    Clin Pharmacol Ther; 2021 Feb; 109(2):471-484. PubMed ID: 32772364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.
    Rhee SJ; Chung H; Yi S; Yu KS; Chung JY
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):973-980. PubMed ID: 28536774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
    Courlet P; Guidi M; Glatard A; Alves Saldanha S; Cavassini M; Buclin T; Marzolini C; Eap CB; Decosterd LA; Csajka C;
    Br J Clin Pharmacol; 2019 Sep; 85(9):2022-2032. PubMed ID: 31144347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
    Kneller LA; Hempel G
    Pharm Res; 2020 May; 37(6):110. PubMed ID: 32476097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens.
    Adiwidjaja J; Gross AS; Boddy AV; McLachlan AJ
    Br J Clin Pharmacol; 2022 Feb; 88(4):1735-1750. PubMed ID: 34535920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling.
    Kinvig H; Cottura N; Lloyd A; Frivold C; Mistilis J; Jarrahian C; Siccardi M
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):855-868. PubMed ID: 36178586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV.
    Calcagno A; Trunfio M; D'Avolio A; Di Perri G; Bonora S
    Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):665-676. PubMed ID: 33913394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
    Moltó J; Rajoli R; Back D; Valle M; Miranda C; Owen A; Clotet B; Siccardi M
    J Antimicrob Chemother; 2017 Mar; 72(3):805-811. PubMed ID: 27999009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
    Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
    Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
    Sayama H; Komura H; Kogayu M; Iwaki M
    J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.
    Stader F; Kinvig H; Penny MA; Battegay M; Siccardi M; Marzolini C
    Clin Pharmacokinet; 2020 Mar; 59(3):383-401. PubMed ID: 31583609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans.
    Teitelbaum Z; Lave T; Freijer J; Cohen AF
    Clin Pharmacokinet; 2010 Sep; 49(9):619-32. PubMed ID: 20690784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
    Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
    Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.